Skip to main content

Kenvue to Announce Fourth Quarter and Full Year 2023 Results on February 8, 2024

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will announce its financial results for the fourth quarter and full year ending December 31, 2023, before market open on February 8, 2024.

The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the financial results. The conference call can be accessed by dialing 888-660-5501 from the U.S. or 646-960-0416 from international locations. The conference ID for all callers is 1558006. A live webcast of the conference call will be available at https://investors.kenvue.com. A replay will be available approximately two hours after the live event.

About Kenvue

Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand Adhesive Bandages, Johnson’s®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we believe in the extraordinary power of everyday care and our teams work every day to put that power in consumers’ hands and earn a place in their hearts and homes. Learn more at www.kenvue.com.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  261.12
-2.87 (-1.09%)
AAPL  267.61
-3.45 (-1.27%)
AMD  334.63
-13.18 (-3.79%)
BAC  52.63
+0.58 (1.11%)
GOOG  348.52
+6.20 (1.81%)
META  678.62
+3.59 (0.53%)
MSFT  424.82
+0.20 (0.05%)
NVDA  216.61
+8.34 (4.00%)
ORCL  172.96
-0.32 (-0.18%)
TSLA  378.67
+2.37 (0.63%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.